Novartis AG Shares Outstanding 2006-2018 | NVS

Novartis AG shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Novartis AG shares outstanding for the quarter ending September 30, 2018 were 2.338B, a 0.89% decline year-over-year.
  • Novartis AG 2017 shares outstanding were 2.317B, a 2.38% decline from 2016.
  • Novartis AG 2016 shares outstanding were 2.374B, a 1.2% decline from 2015.
  • Novartis AG 2015 shares outstanding were 2.403B, a 0.95% decline from 2014.
Novartis AG Annual Shares Outstanding
(Millions of Shares)
2017 2,317
2016 2,374
2015 2,403
2014 2,426
2013 2,479
2012 2,445
2011 2,413
2010 2,301
2009 2,277
2008 2,284
2007 2,329
2006 2,360
2005 2,342
Novartis AG Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 2,338
Q2 2018 2,346
Q1 2018 2,347
Q4 2017 2,317
Q3 2017 2,359
Q2 2017 2,373
Q1 2017 2,389
Q4 2016 2,374
Q3 2016 2,401
Q2 2016 2,401
Q1 2016 2,398
Q4 2015 2,403
Q3 2015 2,438
Q2 2015 2,451
Q1 2015 2,446
Q4 2014 2,426
Q3 2014 2,460
Q2 2014 2,471
Q1 2014 2,479
Q4 2013 2,479
Q3 2013 2,480
Q2 2013 2,490
Q1 2013 2,473
Q4 2012 2,445
Q3 2012 2,445
Q2 2012 2,441
Q1 2012 2,435
Q4 2011 2,413
Q3 2011 2,450
Q2 2011 2,426
Q1 2011 2,305
Q4 2010 2,301
Q3 2010 2,300
Q2 2010 2,297
Q1 2010 2,290
Q4 2009 2,277
Q3 2009 2,285
Q2 2009 2,280
Q1 2009 2,283
Q4 2008 2,284
Q3 2008 2,283
Q2 2008 2,286
Q1 2008 2,273
Q4 2007 2,329
Q3 2007 2,322
Q2 2007 2,352
Q1 2007 2,359
Q4 2006 2,360
Q3 2006 2,362
Q2 2006 2,362
Q1 2006 2,355
Q4 2005 2,342
Q3 2005 2,344
Q2 2005 2,338
Q1 2005 2,341
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $204.469B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.684B 18.32
Pfizer (PFE) United States $262.581B 14.80
Merck (MRK) United States $201.378B 17.45
AbbVie (ABBV) United States $134.913B 11.98
Eli Lilly (LLY) United States $119.915B 21.08
Sanofi (SNY) France $111.886B 13.85
Novo Nordisk (NVO) Denmark $108.835B 17.67
AstraZeneca (AZN) United Kingdom $103.621B 12.86
GlaxoSmithKline (GSK) United Kingdom $101.752B 13.68
Bristol-Myers Squibb (BMY) United States $86.262B 14.21